Health and Human Services Secretary Robert F. Kennedy Jr. announced the cancellation of 22 federal contracts funded by BARDA, totaling nearly $500 million, aimed at advancing mRNA based vaccine development against respiratory viruses such as COVID 19, influenza, and related threats.
The move marks a distinct pivot away from the U.S. government’s pandemic preparedness strategy, which heavily relied on mRNA vaccine platforms following the successful COVID 19 response. Kennedy cited concerns over their diminished effectiveness against rapidly mutating viruses, asserting that even single viral mutations could render the vaccines ineffective. He framed the shift as part of a broader effort to pursue “safer, broader” immunization strategies, such as traditional whole-virus vaccines or alternative platforms less prone to being undermined by viral drift.
Contracts associated with major pharmaceutical firms including Moderna, Pfizer, Sanofi Pasteur, CSL Seqirus, and Tiba Biotech were among those terminated, although some nearing completion will continue through their final stages to preserve prior investments.
Initial reactions from public health and vaccine experts were sharply critical. Dr. Paul Offit referred to the decision as a departure from evidence-based policy, while epidemiologist Michael Osterholm warned it could seriously undermine the nation’s ability to respond quickly to future pandemic threats. Former BARDA director Rick Bright likewise condemned the move as a “strategic misstep” compromising national biodefense readiness.
The decision comes amid broader organizational changes under Kennedy’s leadership at HHS, including restructuring of the CDC’s Advisory Committee on Immunization Practices, removal of multiple professional societies from vaccine working groups, and broader skepticism toward vaccine regulatory frameworks. As the U.S. transitions to flu and respiratory virus season, the consequences of deprioritizing mRNA research are expected to provoke ongoing debate across public health circles and potentially affect vaccine availability during future outbreaks.
